butyrylcholinesterase inhibition

QR Pharma announces FDA clearance to begin trials related to Alzheimer compound
Behavioral Health Central
Sat, 12/4/10 - 12:40 pm
QR Pharma
Alzheimer's disease
bisnorcymserine
butyrylcholinesterase inhibition